Early experience with sunitinib, combined with docetaxel, in patients with metastatic breast cancer

Breast

Volumn 18, Issue 4, 2009, Pages 259-262

  Liljegren, Annelie ^a   Bergh, Jonas ^a   Castany, Roser ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b JULES BORDET INSTITUTE   (Belgium)

Author keywords

Antiangiogenesis; Docetaxel; Metastatic breast cancer; Sunitinib malate; Tyrosine kinase inhibitor

Indexed keywords

ANASTROZOLE; ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EXEMESTANE; FLUOROURACIL; GONADORELIN DERIVATIVE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LETROZOLE; METHOTREXATE; STEROID; SUNITINIB; TAMOXIFEN;

ADJUVANT THERAPY; ADRENAL INSUFFICIENCY; ADULT; ADVANCED CANCER; ANEMIA; ARTHRALGIA; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CASE REPORT; DIARRHEA; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; EPISTAXIS; EXPERIENCE; FACE EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FLUID RETENTION; HEARTBURN; HUMAN; HYPOTENSION; LUNG METASTASIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MASTECTOMY; METASTASIS; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL; NAUSEA; NEUROPATHY; NEUTROPENIA; PAIN; PRIORITY JOURNAL; SENSORY NEUROPATHY; SIDE EFFECT; SPINE METASTASIS; THORAX PAIN; THROMBOCYTOPENIA; TONGUE DISEASE;

ADULT; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INDOLES; LIVER NEOPLASMS; LYMPH NODE EXCISION; MASTECTOMY; MIDDLE AGED; PYRROLES; TAXOIDS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 69749115052     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2009.07.005     Document Type: Article

References (8)

1. Kozloff M., Chuang E., Roy J., Starr A., Gowland P.A., Tarpey M.J., et al. A phase I study of sunitinib plus paclitaxel for first-line treatment of advanced breast cancer: preliminary results. Br Cancer Res Treat 106 (2007) 6078
2. Gianni L., Cardoso F., Mariani G., Isaksson-Friman E., Besse-Hammer T., Vigano L., et al. Exploratory evaluation of a sequential administration of docetaxel and sunitinib in women with advanced breast cancer. Br Cancer Res Treat 106 (2007) 6079
3. Chow L.Q., and Eckhardt S.G. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25 (2007) 884-896
4. Potapova O., Laird A.D., Nannini M.A., Barone A., Li G., Moss K.G., et al. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248. Mol Cancer Ther 5 (2006) 1280-1289
5. Abrams T.J., Lee L.B., Murray L.J., Pryer N.K., and Cherrington J.M. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2 (2003) 471-478
6. Mendel D.B., Laird A.D., Xin X., Louie S.G., Christensen J.G., Li G., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9 (2003) 327-337
7. Christensen JG, Hall C, Hollister BA. Antitumor efficacy of sunitinib malate in concurrent and sequential combinations with standard chemotherapeutic agents in non-small cell lung cancer (NSCLC) nonclinical models. In: Proceedings of the 99th Annual Meeting of the American Association for Cancer Research, San Diego, CA, USA, April 12-16, 2008 (Abstract 1433).
8. Burstein H.J., Elias A.D., Rugo H.S., Cobleigh M.A., Wolff A.C., Eisenberg P.D., et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26 (2008) 1810-1816